Nora Bengoa Vergniory
Group Leader
Ramón y Cajal Fellow, Ikerbasque Research Fellow
Research groups:
Contact
Email:Nora.BV@achucarro.org
Tel.:(+34) 94 601 2095
Science Park UPV/EHU, Sede building
B. Sarriena, s/n
E-48940 Leioa
About me
In 2018 I became an Oxford-BMS/Celgene Research Fellow studying alpha-synuclein aggregation and glial activation in Parkinson’s. I joined the Wade-Martins laboratory in 2015 and have since worked on the role of alpha-synuclein aggregation in Parkinson’s disease.
After graduating I started and Masters in Molecular Biology and Biomedicine, in which I studied the differentiation of human embryonic carcinoma stem cells. This led me to develop an interest in the use of stem cells as models for human neuronal differentiation.
In 2014 I completed a PhD at the University of the Basque Country which focused on the study of the role of Wnt signaling during early neuronal differentiation in human stem cell models.
Selected publications:
Marc Emmenegger, Dr. Elena De Cecco, […], Dr. Nora Bengoa-Vergniory, […], Dr. Mathias Jucker and Dr. Adriano Aguzzi. LAG3 is not expressed in human and murine neurons and does not modulate α-synucleinopathies. EMBO Molecular Medicine, 2021 Jul 26;e14745.
Ryan BJ*, Bengoa-Vergniory N*, […] and Wade-Martins R. Proteomics analysis highlights REST as a potential neuroprotective target for Parkinson’s disease in an alpha synuclein overexpressing BAC-transgenic mouse model. (* equal contribution) Journal of Neuroscience. 2021 Feb 8; JN-RM-1478-20.
Nora Bengoa-Vergniory, […] and Javier Alegre-Abarrategui. Tau-proximity ligation assay reveals extensive previously undetected pathology prior to neurofibrillary tangles in preclinical Alzheimer’s disease. Acta Neuropathologica Communications. 2021 Jan 28;9(1):18.
Bradley M. Roberts, […], Nora Bengoa-Vergniory, Richard Wade-Martins, Peter J. Magill and Stephanie J. Cragg. GABA uptake transporters support dopamine release in dorsal striatum with maladaptive downregulation in a parkinsonism model . Nature communications. 2020 11(1):4958.
Nora Bengoa-Vergniory, Emilie Faggiani, […] and Richard Wade-Martins. CLR01 protects dopaminergic neurons in vitro and in vivo in human neurons and mouse models of Parkinson’s. Nature communications. 2020 11(1):4885.
Butkovich LM, […], Bengoa-Vergniory N , Wade-Martins R, Weinshenker D, Tansey MG. Transgenic mice expressing human alpha-synuclein in noradrenergic neurons develop locus coeruleus pathology and non-motor features of Parkinson’s disease. Journal of Neuroscience. 2020 40(39):7559-7576.
Carroll Rutherford Fields, Nora Bengoa-Vergniory*, Richard Wade-Martins*. Targeting alpha-synuclein as a therapy for Parkinson’s Disease. (* co-corresponding). Frontiers in Molecular Neuroscience. 2019, 12, 255.
Benjamin Henry Mcleod Hunn, Siv Vingill, Sarah Threlfell, Javier Alegre-Abarrategui, Thierry Deltheil, Nora Bengoa-Vergniory, […], Richard Wade-Martins. Impairment of macroautophagy in dopamine neurons has opposing effects on parkinsonian pathology and behaviour. Cell reports. 2019, 29, 4, 920-931.
Federico Zambon, Marta Cherubini, Hugo J R Fernandes, Charmaine Lang, Brent J Ryan, Viola Volpato, Nora Bengoa-Vergniory, […], Richard Wade-Martins. Cellular α-synuclein pathology is associated with bioenergetic dysfunction in Parkinson’s iPSC-derived dopamine neurons. Human molecular genetics . 2019 Jun 15;28(12):2001-2013.
Bengoa-Vergniory N, Roberts RF, Wade-Martins R, Alegre-Abarrategui J. Alpha-synuclein oligomers: a new hope. Acta Neuropathologica. 2017 Dec;134(6):819-838.